Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively. In recent years, these pharma giants have become even more ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

On Monday, Morgan Stanley reaffirmed its positive stance on Eli Lilly (NYSE:LLY) stock, maintaining an Overweight rating and a ...

Eli Lilly (NYSE:LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive ...

Dave Bartosiak's technical analysis approach adds depth to our understanding Eli Lilly’s stock chart. By paying attention to moving averages, support and resistance levels, chart patterns ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best pharma ...